In Arizona, Axolotl Biologix, a regenerative human cell and tissue medical technologies company, entered into an exclusive worldwide license agreement with Protein Genomics, Inc., an R&D company focused on biopolymers for applications in wound healing and tissue regeneration. The license agreement allows Axolotl Biologix to use Protein Genomics’ patents and manufacturing knowledge for a biomimetic skin substitute made from biomaterial called Elastropin. This will help grow and expand Axolotl Biologix’s burn, surgical and wound treatment products. Axolotl Biologix is also acquiring Protein Genomics’ research laboratory in Flagstaff as part of the agreement, and gave a heads up that they plan on filing three new patents in the very near future, so stay tuned.
Home Biomaterials Axolotl Biologix Acquires Protein Genomics’ Research Lab and Signs License Agreement
Latest article
You better be-leaf it: Dawn Bio cultivates wood in a petri dish
In the Netherlands, a startup based at Wageningen University’s campus is pioneering technology to produce wood from cultured cells.
Dubbed Dawn Bio, the company has...
Algae-based snowboards from WNDR get nod from Time Magazine
In Utah, WNDR Alpine’s algae-based snowboards have been named to Time Magazine’s top 200 inventions list.
Unlike most snowboards, which are made out of petroleum-based...
Prince William’s Earthshot Prize names seaweed firm Coast 4C as a finalist
In Australia, a startup sustainably cultivating seaweed has been chosen as a finalist for Prince William’s 2024 Earthshot Prize.
Coast 4C works with farmers in...